Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profiling of MDA_MB_231 cell line in response to treatment with Dexamethasone and SH4-54

ABSTRACT: Gene expression profiling of MDA_MB_231 cell line in response to treatment with Dexamethasone and SH4-54

PROVIDER: PRJNA565792 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10126643.fastq.gz	Fastqsanger.gz
	SRR10126644.fastq.gz	Fastqsanger.gz
	SRR10126645.fastq.gz	Fastqsanger.gz
	SRR10126646.fastq.gz	Fastqsanger.gz
	SRR10126647.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Gene expression profiling of MDA_MB_231 cell line in response to treatment with Dexamethasone and SH4-54

Project description:To determine how the transcription factors GR and STAT3 cooperate to regulate gene expression, the MDA-MB-231 breast cancer cell line was treated with dexamethasone (1µM for 24 hours) and the STAT3 inhibitor SH4-54 (8µM for 24 hours) alone and in combination. A multivariate linear model with a GR:STAT3 interaction term was used to identify genes that are differentially expressed when both TFs are fully active in the nucleus.

2020-08-21 | GSE137535 | GEO

Rat liver: Dexamethasone treatment vs. Control

Project description:Sixteen male Sprague-Dawley rats were randomly allocated into 2 groups (8 rats per group) as follows: the control group (CON) and the dexamethasone-treated group (DEXA). Dexamethasone-treated rats received a daily intraperitoneal injection of 1.5 mg/kg of dexamethasone for 5 days. All rats were fasted during the night following the fifth day. On the sixth day, the animals were killed by decapitation. In order to focus our investigation on metabolism-related genes, we developed a metabolism dedicated microarray tool: the Mitoligo. Using this microarray tool, we were able to determine that energy metabolism was deeply modified by dexamethasone treatment. Dexamethasone treatment to rats induces a complete switch of the metabolism toward a maximal rate of ATP synthesis. In this study, we show that substrate supplying for oxidative phosphorylation is greatly enhanced. We also confirm that oxidative phosphorylation capacity is increased by dexamethasone treatment. Keywords: hormonal treatment

2008-01-13 | GSE9035 | GEO

Dexamethasone treatment of VCaP prostate cells

Project description:The treatment of advanced prostate cancer has been transformed by novel antiandrogen therapies such as enzalutamide. We identified glucocorticoid receptor (GR) activity as modulator of enzalutamite sensitivity in the VCaP prostate cancer cell line. The GR agonist dexamethasone was sufficient to confer enzalutamide resistance whereas a GR antagonist restored sensitivity. These expression profiling data demonstrate that GR transcriptional activity overlaps with that of AR in the VCAP model.

2013-12-27 | GSE51872 | GEO

Expression data from H295R_GRα cells following treatment with dexamethasone or RU486

Project description:The human glucocorticoid receptor (GRα) is overexpressed at the molecular and protein level in malignant human adrenocortical cancers. A stable cell line model of GRα overexpression was established using the H295R human adrenocortical cancer cell line. The following results were obtained from gene expression profiling of H295R_GRα and H295R_Control (empty vector) cells following treatment with either a GRα agonist (dexamethasone), GRα antagonist (RU486) or vehicle (ethanol) control.

2015-01-10 | GSE64826 | GEO

hCMEC/D3 cell line with single atorvastatin,single dexamethasone or low-dexamenthasone and atorvastatin treatment after hematoma injuried

Project description:Some studies have revealed that treating chronic subdural hematoma (CSDH) with drugs is effective; however, the specific mechanism of this process has been seldom discussed. Herein, we sought to identify the potential underlying mechanism of atorvastatin and low-dose dexamethasone for CSDH treatment. We sequenced the hCMEC/D3 cell lines treated with single statin, dexamethasone and low dose dexamethasone after hematoma injuried and statin to find out the key point.

2019-10-22 | GSE139133 | GEO

Expression data from H295R_GRÎ± cells following treatment with dexamethasone or RU486

Project description:The human glucocorticoid receptor (GRÎ±) is overexpressed at the molecular and protein level in malignant human adrenocortical cancers. A stable cell line model of GRÎ± overexpression was established using the H295R human adrenocortical cancer cell line. The following results were obtained from gene expression profiling of H295R_GRÎ± and H295R_Control (empty vector) cells following treatment with either a GRÎ± agonist (dexamethasone), GRÎ± antagonist (RU486) or vehicle (ethanol) control. H295R_GRÎ± and H295R_Control (empty vector) cells were treated in triplicate for 6 hours with dexamethasone 100 nM, RU486 100 nM or vehicle (ethanol) control.

2015-01-10 | E-GEOD-64826 | biostudies-arrayexpress

Effects of dexamethasone on gene expression in rat pancreatic AR42J cell line

Project description:The rat pancreatic cell line AR42J is relatively undifferentiated under normal culture conditions. When the glucocorticoid dexamethasone is added to the medium the cells display a dramatic decrease in proliferative rate and are induced to a more exocrine phenotype that includes increased expression of exocrine pancreas products (digestive enzymes) and more developed regulated secretion. We used microarray to determine changes in gene expression comparing control (without dexamethasone) vs induced (plus dexamethasone).

2015-09-11 | GSE72907 | GEO

Dexamethasone treatment of VCaP prostate cells

2013-12-27 | E-GEOD-51872 | biostudies-arrayexpress

RNAs bound by the glucocorticoid receptor during dexamethasone treatment

Project description:RNAs bound by the glucocorticoid receptor during dexamethasone treatment

| PRJNA901183 | ENA

Variovorax sp. 54 strain:54

Project description:Variovorax sp. 54 strain:54 Genome sequencing and assembly

| PRJNA402417 | ENA